BiosPacific Revenue and Competitors
Estimated Revenue & Valuation
- BiosPacific's estimated annual revenue is currently $1.4M per year.
- BiosPacific's estimated revenue per employee is $155,000
Employee Data
- BiosPacific has 9 Employees.
- BiosPacific grew their employee count by -10% last year.
BiosPacific's People
Name | Title | Email/Phone |
---|---|---|
1 | Managing Director | Reveal Email/Phone |
2 | Senior Manager Business Development | Reveal Email/Phone |
3 | European Business Development Manager | Reveal Email/Phone |
4 | Sales Support Manager | Reveal Email/Phone |
BiosPacific Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is BiosPacific?
As a manufacturer and supplier of antibodies and antigens of exceptional quality, for more than 30 years now, BiosPacific is experienced in meeting the rigorous demands of the industrial client. Our success has been due, in large part, to our commitment to find the most effective solutions for your individual needs. Our expansive range of monoclonal antibodies, affinity purified polyclonal antibodies and purified proteins for immunoassay development allows us to support our customers collaboratively from feasibility to manufacturing.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $1.2M | 10 | 11% | N/A |
#3 | $0.9M | 10 | 0% | N/A |
#4 | $0.9M | 10 | N/A | N/A |
#5 | $1M | 11 | 10% | N/A |